Epstein Secrets

feedback. Best regards, Paul Paul W. Finnegan, MD, MBA Chief Executive Officer Angiocrine Bioscience, Inc. 3570 Cannel Mountain Rd. Suite 200, San Diego, CA 92130 From: Paul Finnegan Sent: Wednesday, September 2, 2015 7:12 AM To: [email protected]' <[email protected]>; Cc: Jeffrey Port

From: Paul Finnegan c:a To: "jeevacation®gmail.com" <jeevacation®gmail.com> Cc: Jeffrey Port < Subject: RE: Angiocrine Bioscience Update Date: Tue, 15 Mar 2016 01:09

ar-and-a-half since we met at your residence in Manhattan. Since then Angiocrine team and programs have progressed forward. We moved the company to San Diego. We were awarded a $3.8M non-dilutive grant from CIRM, the State of California funding agency for regenerative medicine and stem cell therapy. Tha

oscienceinvestor May_2017_v170504_1813.pdf; Angiocrinen Series_A- I_Equity_Term_Sheet_FINAL.pdf Sent from my iPhone Begin forwarded message: From: Paul Finnegan • Date: May 7, 2017 at 4:03:08 PM EDT To: " Cc: Jeffrey Port Subject: RE: Intro via Di- Jeff Port - Angiocrine Bioscience Update Dear Jeffrey,

tfont-family:"Arial",sans-seritcolo=1222222"> Chief Executive Officer Angiocrine Bioscience, Inc.4=pan> 3570 Carmel Mountain Rd, Suite 200,=/o:p> San Diego, CA 92130 Angiocrine Bioscience Research Weill Cornell Medical College, Medical R=search Building A-335 1300 York Avenue, New York, NY 10065 2

From: Sent: To: Cc: Subject: Attachments: Dear Jeffrey, Paul Finnegan Wednesda , Se. em er , : Jeffrey Port Angiocrine Bioscience "numbers". requested Angiocrine - Capitalization Table (2015.7.10) Summary v150901.p